Labcorp (LH) Inaccurate Prenatal Tests Case

• In January 2022, the NYT article questioned the accuracy of certain prenatal tests offered by Labcorp (LH).

• On it, $LH fell 5%, losing $1.36B+ of shareholder value.

• Investors may have grounds to suspect that Labcorp runs inadequate quality control of its tests’ operation, which led to thier losses.

On January 1, 2022, NYT article questioned the accuracy of certain prenatal tests, alleging that:

• positive test results on tests are about 85 percent incorrect,

• positive results require expensive follow-up testing with a small risk of miscarriage, that can’t be performed until later in pregnancy.

On this news, $LH fell 5% and lost over $1.36 billion of its market capitalization, seriously damaging shareholders.

Considering all the information, investors might have grounds to suspect that Labcorp failed to timely disclose the Company’s quality control setbacks, which consequently led to their losses.

The case is already under investigation by at least one of the reputable law firms.